Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Lucira Health stock

LHDXQ
US54948U1051

Price

0.00
Today +/-
+0
Today %
+0 %
P

Lucira Health stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Lucira Health stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Lucira Health stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Lucira Health stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Lucira Health's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Lucira Health Stock Price History

DateLucira Health Price
10/4/20230.00 undefined
10/3/20230.00 undefined

Lucira Health Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Lucira Health, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Lucira Health from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Lucira Health’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Lucira Health. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Lucira Health’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Lucira Health’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Lucira Health’s growth potential.

Lucira Health Revenue, EBIT and net profit per share

DateLucira Health RevenueLucira Health EBITLucira Health Net Income
2023e128.75 M undefined-32.19 M undefined-24.25 M undefined
2022e228.92 M undefined-156.81 M undefined-9.62 M undefined
202193.06 M undefined-57.2 M undefined-64.83 M undefined
2020269,000 undefined-31.93 M undefined-37.35 M undefined

Lucira Health Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
202020212022e2023e
093228128
--145.16-43.86
-19.35--
-11800
-31-57-156-32
--61.29-68.42-25.00
-37-64-9-24
-72.97-85.94166.67
36.9634.7700
----
Details

Keystats

ⓘ

Revenue and Growth

The Lucira Health Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Lucira Health is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201920202021
     
4.158.21105.98
00.2927.25
00.188.19
04.8750.78
0.246.6814.09
4.3470.23206.28
1.4320.1633.69
000
000
000
000
0.052.320.38
1.4722.4734.07
5.8192.7240.35
     
30.97121.080.04
0.691.4317.3
-26.37-63.71-128.54
000
000
5.2958.77188.8
0.573.9819.37
1.034.8829.22
001.74
000
000
1.68.8650.33
024.690
000
0.710.381.22
0.7125.071.22
2.3133.9351.55
7.6192.7240.35
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Lucira Health provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Lucira Health's financial health and stability.

Assets

Lucira Health's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Lucira Health must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Lucira Health after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Lucira Health's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201920202021
-8-37-64
003
000
0-3-57
1817
000
000
-7-32-100
0-18-15
0-18-15
000
000
0310
1076161
11107161
---
000
45645
-7.14-51.34-116.27
000

Lucira Health stock margins

The Lucira Health margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Lucira Health. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Lucira Health.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Lucira Health's sales revenue. A higher gross margin percentage indicates that the Lucira Health retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Lucira Health's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Lucira Health's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Lucira Health's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Lucira Health. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Lucira Health's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Lucira Health Margin History

Lucira Health Gross marginLucira Health Profit marginLucira Health EBIT marginLucira Health Profit margin
2023e19.52 %-25 %-18.84 %
2022e19.52 %-68.5 %-4.2 %
202119.52 %-61.47 %-69.67 %
2020-621.56 %-11,868.03 %-13,884.02 %

Lucira Health Stock Sales Revenue, EBIT, Earnings per Share

The Lucira Health earnings per share therefore indicates how much revenue Lucira Health has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Lucira Health earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Lucira Health's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Lucira Health’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Lucira Health's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Lucira Health Revenue, EBIT and net profit per share

DateLucira Health Sales per ShareLucira Health EBIT per shareLucira Health Earnings per Share
2023e3.17 undefined0 undefined-0.6 undefined
2022e5.64 undefined0 undefined-0.24 undefined
20212.68 undefined-1.65 undefined-1.86 undefined
20200.01 undefined-0.86 undefined-1.01 undefined

Lucira Health business model

Lucira Health is an American company specializing in the development and manufacturing of diagnostic devices and kits. It was founded in 2013 and is headquartered in Emeryville, California. The company was founded by Dr. Erik Engelson and Dr. Jessie Zhou, both of whom have experience in developing molecular diagnostic tests. Lucira Health initially provided research and development services for other companies before deciding to develop its own products. In 2018, the company won first place in the XPRIZE Rapid-Response COVID-19 competition and received a $5 million award for the development of a rapid COVID-19 test. Lucira Health's business model focuses on the development and manufacturing of diagnostic devices and kits. The company works closely with other organizations to develop faster, more effective, and cost-efficient tests. It also utilizes partnerships and licensing agreements to market its devices and tests. Lucira Health has two main divisions: molecular diagnostics and point-of-care diagnostics. In molecular diagnostics, the company offers a range of tests specifically designed for molecular diagnostics, including tests for diagnosing infectious diseases such as COVID-19, influenza, and hepatitis B and C. In point-of-care diagnostics, Lucira Health specializes in the development of point-of-care diagnostic devices that are designed to deliver fast and accurate test results within minutes. The company has developed the first FDA-approved COVID-19 test kit that can be used at home. The test kit provides results within 30 minutes and requires only a nasal swab. In addition to its diagnostic products, the company has also developed a platform that allows users to submit and track their test results online. In conclusion, Lucira Health is a company focused on the development of diagnostic devices and kits. With its emphasis on molecular and point-of-care diagnostics, the company has developed a range of tests that can be used to diagnose infectious diseases. With its history of collaboration with other organizations and the $5 million award from the XPRIZE Rapid-Response COVID-19 competition, Lucira Health is expected to continue developing innovative products that contribute to the improvement of public health. Lucira Health is one of the most popular companies on Eulerpool.com.

Lucira Health SWOT Analysis

Strengths

Lucira Health Inc has several key strengths that contribute to its success in the market:

Lucira Health Inc has developed innovative and cutting-edge technology, allowing for the development and production of rapid at-home diagnostic tests. This technology provides convenience and accessibility to users, especially during times when visiting healthcare facilities may be challenging or inconvenient.

The company offers a diverse range of diagnostic tests targeting various infectious diseases. Their product portfolio includes tests for COVID-19, influenza, and more. This wide range of products enables Lucira Health Inc to cater to different market segments and increases their revenue potential.

Lucira Health Inc has successfully obtained regulatory approvals for its products. This demonstrates the company's commitment to ensuring the safety and effectiveness of their diagnostic tests, instilling trust in both consumers and healthcare professionals.

Weaknesses

While Lucira Health Inc has numerous strengths, it also faces certain weaknesses that may hinder its growth:

Although Lucira Health Inc has made significant progress in establishing its presence in the market, it still faces competition from well-established players. This limits the company's market share and poses challenges in gaining broader brand recognition.

The pricing of Lucira Health Inc's diagnostic tests might be relatively higher compared to alternatives available in certain markets. This could discourage price-sensitive customers from choosing their products, potentially affecting market penetration and adoption rates.

Opportunities

Lucira Health Inc can leverage various opportunities to further expand its business:

With the ongoing COVID-19 pandemic, there is a growing demand for at-home testing solutions. Lucira Health Inc can capitalize on this trend by continuously developing and promoting their at-home diagnostic tests, targeting both individual consumers and healthcare institutions.

Lucira Health Inc can explore opportunities to expand its market reach beyond its current geographic locations. By strategically partnering with distributors and entering new markets, the company can tap into the global demand for reliable and rapid diagnostic testing.

Threats

There are potential threats that Lucira Health Inc should be aware of:

Lucira Health Inc operates in a highly competitive healthcare industry where other companies are also developing and marketing rapid diagnostic tests. Intense competition may pose challenges in terms of pricing, differentiation, and market share.

Changes in healthcare regulations and requirements may affect the approval process for diagnostic tests. Lucira Health Inc must continuously monitor and adapt to any regulatory changes to ensure compliance and avoid potential delays in product launches.

Lucira Health Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Lucira Health historical P/E ratio, EBIT multiple, and P/S ratio

Lucira Health shares outstanding

The number of shares was Lucira Health in 2023 — This indicates how many shares 34.769 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Lucira Health earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Lucira Health's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Lucira Health’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Lucira Health's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for Lucira Health.

Lucira Health latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2022-0.39 -3.15  (-697.87 %)2022 Q3
6/30/2022-0.35 -0.45  (-28.5 %)2022 Q2
3/31/2022-0.08 0.4  (585.44 %)2022 Q1
12/31/2021-0.56 0.01  (101.78 %)2021 Q4
9/30/2021-0.53 -0.47  (11.1 %)2021 Q3
6/30/2021-0.33 -0.38  (-15.29 %)2021 Q2
3/31/2021-0.34 -0.54  (-58.87 %)2021 Q1
1

Lucira Health shareholders

%
Name
Stocks
Change
Date
15.32992 % Eclipse ventures , LLC6,223,795012/31/2022
5.52149 % Yen (Tuff)2,241,668-51,3344/20/2022
1.78742 % EPIQ Capital Group, LLC725,675-13,011,69512/31/2022
1.53572 % The Vanguard Group, Inc.623,488-8,27912/31/2022
1.07599 % Citi Investment Research (US)436,840-181,80312/31/2022
0.92456 % Mitra (Debkishore)375,363-1919/1/2022
0.76416 % Engelson (Erik T.)310,241-60,0003/3/2023
0.71164 % Boeding (Chad)288,918288,91812/14/2022
0.66914 % Lamond (David A.)271,66604/20/2022
0.66758 % Balyasny Asset Management LP271,030-55,16812/31/2022
1
2
3
4
5
...
10

Lucira Health Executives and Management Board

Mr. Erik Engelson(61)
Lucira Health President, Chief Executive Officer, Director (since 2019)
Compensation 775,017
Ms. Kelly Lewis Brezoczky(57)
Lucira Health Executive Vice President - Commercialization, Regulatory, Clinical and Business Development
Compensation 736,120
Dr. Debkishore Mitra(34)
Lucira Health Chief Technology Officer
Compensation 626,884
Ms. Sandra Gardiner(56)
Lucira Health Independent Director
Compensation 117,342
Mr. David Lamond(47)
Lucira Health Independent Director
Compensation 117,342
1
2
3

Most common questions regarding Lucira Health

What values and corporate philosophy does Lucira Health represent?

Lucira Health Inc represents key values such as innovation, efficiency, and quality in the healthcare industry. The company aims to revolutionize healthcare by developing convenient and accessible diagnostic solutions. With a focus on empowering individuals to take charge of their health, Lucira Health Inc has a strong corporate philosophy centered around enhancing patient outcomes and improving overall well-being. By leveraging cutting-edge technology and expertise, Lucira Health Inc strives to provide accurate and timely diagnostic tools that can be easily used at home or in point-of-care settings.

In which countries and regions is Lucira Health primarily present?

Lucira Health Inc is primarily present in the United States.

What significant milestones has the company Lucira Health achieved?

Lucira Health Inc has achieved several significant milestones. Firstly, in November 2020, the company received Emergency Use Authorization (EUA) from the FDA for its COVID-19 All-In-One Test Kit, becoming the first prescription, at-home molecular diagnostic test for COVID-19. This milestone marked a breakthrough in accessible and accurate testing during the pandemic. Additionally, Lucira Health Inc expanded its distribution partnership with the global pharmaceutical company, GlaxoSmithKline, in March 2021. This collaboration aimed to increase the availability of Lucira's COVID-19 at-home test kits in the United States. These milestones highlight Lucira Health Inc's commitment to innovative, convenient, and reliable diagnostic solutions.

What is the history and background of the company Lucira Health?

Lucira Health Inc is a leading healthcare company specializing in providing innovative, accessible, and reliable diagnostic testing solutions. Established in [year], Lucira Health has a strong emphasis on developing rapid molecular diagnostic tests for various infectious diseases. The company's commitment to revolutionizing healthcare has resulted in the development of its FDA-authorized Lucira™ COVID-19 All-In-One Test Kit, which offers individuals the convenience of at-home testing. Lucira Health's groundbreaking technology aims to improve patient outcomes and access to accurate diagnostics. With a focus on delivering efficient and reliable solutions, Lucira Health continues to make strides in the field of healthcare diagnostics.

Who are the main competitors of Lucira Health in the market?

The main competitors of Lucira Health Inc in the market include companies like Abbott Laboratories, Quidel Corporation, and Becton, Dickinson and Company (BD).

In which industries is Lucira Health primarily active?

Lucira Health Inc is primarily active in the healthcare industry.

What is the business model of Lucira Health?

The business model of Lucira Health Inc. revolves around providing accessible and convenient diagnostic testing solutions. Lucira Health Inc. specializes in developing and manufacturing innovative at-home rapid molecular testing platforms for various infectious diseases, including COVID-19. Through their proprietary technologies, Lucira Health Inc. enables individuals to easily detect and monitor their health conditions in the comfort of their own homes. Their user-friendly testing kits deliver accurate results within a short timeframe, promoting early intervention and timely treatment. Lucira Health Inc.'s business model aims to empower individuals, healthcare providers, and public health agencies by offering reliable and cost-effective testing solutions.

What is the P/E ratio of Lucira Health 2024?

The P/E ratio cannot be calculated for Lucira Health at the moment.

What is the P/S ratio of Lucira Health 2024?

The P/S cannot be calculated for Lucira Health currently.

What is the Quality Investing of Lucira Health?

The Quality Investing for Lucira Health is 2/10.

What is the revenue of Lucira Health 2024?

The revenue cannot currently be calculated for Lucira Health.

How high is the profit of Lucira Health 2024?

The profit cannot currently be calculated for Lucira Health.

What is the business model of Lucira Health

Lucira Health Inc is a US-based company that offers medical devices and solutions in the field of in-vitro diagnostics. The company focuses on the needs of consumers and healthcare facilities and provides innovative solutions for conducting tests for various diseases and conditions quickly, easily, and reliably. Their business model encompasses the development, manufacturing, and marketing of diagnostic and monitoring solutions for a wide range of medical conditions, including HIV, hepatitis, and COVID-19. Their main product is a home-use COVID-19 test kit, which was approved by the FDA in November 2020. They also offer other products, such as a home-use rapid influenza test, as well as diagnostic solutions for hemoglobin, bilirubin, and glucose. Lucira Health Inc markets and distributes its products through various channels, including direct sales to healthcare facilities and online marketplaces like Amazon and Walmart. They have also signed an agreement with Grifols, a leading biotechnology company, to distribute their products in Europe and Latin America. The company collaborates closely with clinical partners and research institutions to develop and improve their products and solutions. Lucira Health Inc is well-positioned to grow and thrive in the in-vitro diagnostics market, thanks to its emphasis on collaboration and innovation.

What is the Lucira Health dividend?

Lucira Health pays a dividend of 0 USD distributed over payouts per year.

How often does Lucira Health pay dividends?

The dividend cannot currently be calculated for Lucira Health or the company does not pay out a dividend.

What is the Lucira Health ISIN?

The ISIN of Lucira Health is US54948U1051.

What is the Lucira Health ticker?

The ticker of Lucira Health is LHDXQ.

How much dividend does Lucira Health pay?

Over the past 12 months, Lucira Health paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Lucira Health is expected to pay a dividend of 0 USD.

What is the dividend yield of Lucira Health?

The current dividend yield of Lucira Health is .

When does Lucira Health pay dividends?

Lucira Health pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Lucira Health?

Lucira Health paid dividends every year for the past 0 years.

What is the dividend of Lucira Health?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Lucira Health located?

Lucira Health is assigned to the 'Health' sector.

Wann musste ich die Aktien von Lucira Health kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Lucira Health from 11/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/3/2024.

When did Lucira Health pay the last dividend?

The last dividend was paid out on 11/3/2024.

What was the dividend of Lucira Health in the year 2023?

In the year 2023, Lucira Health distributed 0 USD as dividends.

In which currency does Lucira Health pay out the dividend?

The dividends of Lucira Health are distributed in USD.

All fundamentals about Lucira Health

Our stock analysis for Lucira Health Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lucira Health Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.